Efficacy of Different Acid Suppressors in Bismuth-containing Quadruple Therapy Against Helicobacter Pylori

Shandong University

Status: Completed

Conditions: Helicobacter Pylori; Eradication Rate

Treatments: Other: PPI regimen; Other: P-CAB regimen

Study type: Observational

Funder types: Other

Identifiers

NCT05301725

2022-SDU-QILU-G001

Details and patient eligibility

About

Ａretrospective study was conducted to compare the efficacy, safety, and cost-effectiveness of traditional proton pump inhibitors (PPI ) and Potassium-competitive acid blockers ( P-CAB )for clarithromycin-based bismuth-containing quadruple therapy in the management of Helicobacter pylori eradication.

Full description

This study retrospectively enrolled participants with H. pylori infection who received bismuth quadruple regimen containing clarithromycin. The basic information, treatment results, adverse reactions and compliance of the patients were collected. According to the type of acid inhibitors, participants were divided into traditional PPI group and P-CAB group. Traditional PPI group which were divided into lansoprazole group and esomeprazole group. The eradication rate, safety, compliance of H. pylori in different treatment regimens was evaluated. Multivariate analysis was performed to identify predictors of eradication failure.

Enrollment: 670 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants aged 18-75 years with persistent H. pylori infection.
• Participants received clarithromycin-based bismuth-containing quadruple therapy.

Exclusion criteria

• Patients received rescue therapy
• Patients treated with PPI, P-CAB,bismuth and antibiotics in the previous 4 weeks
• Patients with gastorectomy
• Currently pregnant or lactating or other conditions unable to receive therapy
• Severe concomitant cardiovascular, respiratory, or endocrine diseases, clinically significant renal or hepatic disease, hematologic disorders and any other clinically significant medical condition that could increase risk
• Severe neurologic or psychiatric disorders
• Information incomplete

Trial design

670 participants in 2 patient groups

PPI group

Description:

PPI regimen

Treatment:

Other: PPI regimen

P-CAB group

Description:

P-CAB regimen

Treatment:

Other: P-CAB regimen